Characterizing the clinical features and atrophy patterns of MAPT-Related Frontotemporal Dementia with disease progression modeling by Young, Alexandra L. et al.
RESEARCH ARTICLE OPEN ACCESS
Characterizing the Clinical Features and Atrophy
Patterns of MAPT-Related Frontotemporal
Dementia With Disease Progression Modeling
Alexandra L. Young, PhD, Martina Bocchetta, PhD, Lucy L. Russell, PhD, Rhian S. Convery, MSc,
Georgia Peakman, MSc, Emily Todd, MRes, David M. Cash, PhD, Caroline V. Greaves, BSc,
John van Swieten, MD, Lize Jiskoot, PhD, Harro Seelaar, MD, PhD, Fermin Moreno, MD,
Raquel Sanchez-Valle, MD, Barbara Borroni, MD, Robert Laforce, Jr., MD, Mario Masellis, MD, PhD,
Maria Carmela Tartaglia, MD, Caroline Graff, MD, Daniela Galimberti, PhD, James B. Rowe, FRCP, PhD,
Elizabeth Finger, MD, Matthis Synofzik, MD, Rik Vandenberghe, MD, Alexandre de Mendonça, MD, PhD,
Fabrizio Tagliavini, MD, Isabel Santana, MD, Simon Ducharme, MD, Chris Butler, FRCP PhD,
Alex Gerhard, MRCP, MD, Johannes Levin, MD, Adrian Danek, MD, Markus Otto, MD, Sandro Sorbi,








Mutations in the MAPT gene cause frontotemporal dementia (FTD). Most previous studies
investigating the neuroanatomical signature of MAPT mutations have grouped all different
mutations together and shown an association with focal atrophy of the temporal lobe. The
variability in atrophy patterns between each particular MAPT mutation is less well-character-
ized. We aimed to investigate whether there were distinct groups of MAPT mutation carriers
based on their neuroanatomical signature.
Methods
We applied Subtype and Stage Inference (SuStaIn), an unsupervised machine learning tech-
nique that identifies groups of individuals with distinct progression patterns, to characterize
patterns of regional atrophy in MAPT-associated FTD within the Genetic FTD Initiative
(GENFI) cohort study.
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Results
Eighty-twoMAPT mutation carriers were analyzed, the majority of whom had P301L, IVS10+16, or R406W mutations, along
with 48 healthy noncarriers. SuStaIn identified 2 groups ofMAPT mutation carriers with distinct atrophy patterns: a temporal
subtype, in which atrophy was most prominent in the hippocampus, amygdala, temporal cortex, and insula; and a fronto-
temporal subtype, in which atrophy was more localized to the lateral temporal lobe and anterior insula, as well as the
orbitofrontal and ventromedial prefrontal cortex and anterior cingulate. There was one-to-one mapping between IVS10+16 and
R406W mutations and the temporal subtype and near one-to-one mapping between P301L mutations and the frontotemporal
subtype. There were differences in clinical symptoms and neuropsychological test scores between subtypes: the temporal
subtype was associated with amnestic symptoms, whereas the frontotemporal subtype was associated with executive
dysfunction.
Conclusion
Our results demonstrate that different MAPT mutations give rise to distinct atrophy patterns and clinical phenotype,
providing insights into the underlying disease biology and potential utility for patient stratification in therapeutic trials.
Frontotemporal dementia (FTD) is a heterogeneous disorder
characterized by behavioral and language difficulties. Approxi-
mately one-third of cases are inherited on an autosomal dominant
basis, with the majority being due to mutations in progranulin
(GRN), chromosome 9 open reading frame 72 (C9orf72), or
microtubule-associated protein tau (MAPT).1 Previous studies
have shown that the heterogeneity of FTD is in part related to
distinct clinical features and atrophy patterns between these dif-
ferent genetic groups.2,3 However, there can also be substantial
phenotypic heterogeneity within each genetic group.4
Although more than 70 MAPT mutations have been iden-
tified to date, only a few are common, with P301L,
IVS10+16, and R406W being the most frequently de-
scribed.5 Within-group pathologic heterogeneity in MAPT
mutation carriers is related to the location of the mutation in
the gene,6 and there is some evidence that phenotypic het-
erogeneity is similarly affected by the position of the
mutation.5,7 However, studying the effect of specific muta-
tions on disease phenotype is difficult because there are
typically only a few individuals with each particular muta-
tion. Here we took the reverse approach, in which we used an
unsupervised learning technique—Subtype and Stage In-
ference (SuStaIn)4—to identify subgroups within MAPT
mutation carriers with similar atrophy patterns. This enabled
us to compare the MAPT mutations of individuals assigned
to each subtype, providing greater statistical power than
considering each mutation separately. Moreover, the SuS-
taIn subtypes account for heterogeneity in disease stage,
improving the accuracy of the subtyping assignments4 by
removing a key confound from the analysis and enabling
subtyping of presymptomatic individuals. We further com-
pared the clinical phenotypes of each subtype to gain insight
into the relationship between MAPT mutation, atrophy
pattern, and clinical presentation.
Methods
Participants
The Genetic FTD Initiative (GENFI) is a cohort study en-
rolling symptomatic carriers of mutations in the genes causing
FTD as well as their adult (>age 18) at-risk first-degree rel-
atives (i.e., both presymptomatic mutation carriers and people
who are mutation-negative; i.e., noncarriers). For this study,
all MAPT mutation carriers (82 total: 25 symptomatic, 57
presymptomatic) who had cross-sectional volumetric T1-
weighted MRI data available from Data Freeze 4 of GENFI2
were selected for inclusion in our analysis. As a control pop-
ulation for z scoring imaging data, we used data from 300
noncarriers from the GENFI cohort with available cross-
sectional volumetric MRI. As a control population for statis-
tical testing, we used data from the 48 of these noncarriers
who were first-degree relatives of known symptomatic carriers
of mutations in the MAPT gene. Fifty of the 82 MAPT mu-
tation carriers had follow-up MRI scans at 1 or more time
points (total of 92 follow-up scans available), which were used
to check the consistency of the SuStaIn subtype and stage
assignments at follow-up.
Standard Protocol Approvals, Registrations,
and Patient Consents
Local ethics committees at each of the sites approved the
study and all participants provided informed written consent.
Imaging Data
The acquisition and postprocessing procedures have been de-
scribed previously.2 Briefly, cortical and subcortical volumes
Glossary
CBI-R = Cambridge Behavioural Inventory–revised; CDR = Clinical Dementia Rating; EYO = estimated years from onset;
FTD = frontotemporal dementia; GENFI = Genetic FTD Initiative; GIF = geodesic information flow; SuStaIn = Subtype and
Stage Inference; TMT = Trail Making Test.
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were generated using a multiatlas segmentation propaga-
tion approach known as geodesic information flow (GIF)8
on T1-weighted MRI. The volumes of 19 cortical and 7
subcortical regions were calculated comprising the orbi-
tofrontal cortex, dorsolateral prefrontal cortex, ventrome-
dial prefrontal cortex, motor cortex, opercular cortex, frontal
pole, medial temporal cortex, lateral temporal cortex, temporal
pole, supratemporal cortex, medial parietal cortex, lateral pari-
etal cortex, sensory cortex, occipital cortex, anterior cingulate
cortex, middle cingulate cortex, posterior cingulate cortex, an-
terior insular cortex, posterior insular cortex, amygdala, hippo-
campus, caudate, putamen, nucleus accumbens, globus pallidus,
and thalamus. The total cerebellar volume was also calculated. A
list of the GIF subregions included in each cortical region is
included in eTable 1 (doi.org/10.5061/dryad.rxwdbrv83). All
volumes were corrected for head size (total intracranial volume
calculated using SPM 129), scanner field strength (1.5T or 3T),
age, and sex by estimating a linear regression model in a control
population of 300 noncarriers (see Methods: Participants) and
then propagating this model to the MAPT mutation carriers.
There were no significant differences in head size (p = 0.80, t
test), field strength (p = 0.37, χ2 test), age (p = 0.56, t test), or
sex (p = 0.35, χ2 test) between theMAPTmutation carriers and
the control population, and the control population covered a
wider age range than the mutation carriers. The corrected vol-
umes were then converted into z scores relative to the control
population for use as input to SuStaIn, giving the control
population a mean of 0 and an SD of 1. As regional brain
volumes decrease with disease progression, the z scores become
negative as the disease progresses. For simplicity, we multiplied
the z scores by −1, giving positive z scores that increase with
disease progression.
Genetic Data
Sequencing was performed at each site to determine the
presence of the specificMAPT mutation. To avoid unblinding
of genetic status (mutation carrier or noncarrier) for individuals
from families with rare mutations, in the presymptomatic
mutation carrier group we only report the individual mutations
if there are also noncarriers with that particular mutation, or for
individuals who converted to being symptomatic during fol-
low-up.
Clinical Data and Neuropsychology
All participants underwent the standard GENFI clinical and
neuropsychological assessment.2 The GENFI clinical as-
sessment includes noting the presence of behavioral, neu-
ropsychiatric, language, cognitive, and motor symptoms on
a scale similar to the Clinical Dementia Rating (CDR) in-
strument with 0 representing no symptoms, 0.5 question-
able or very mild symptoms, and 1, 2, and 3 representing
mild, moderate, and severe symptoms, respectively.10 The
revised version of the Cambridge Behavioural Inventory
(CBI-R) was also performed.11 The neuropsychological
battery included the Wechsler Memory Scale–Revised
Digit Span forward and backward (total score), the Trail
Making Test (TMT) A and B (total time to complete and
number of errors noted), Wechsler Adult Intelligence
Scale–Revised Digit Symbol, Boston Naming Test (30-
item modified version), verbal fluency (category and pho-
nemic), and Wechsler Abbreviated Scale of Intelligence
Block Design (total score).2
Subtype and Stage Inference
SuStaIn was used to identify subgroups of MAPT muta-
tion carriers with distinct progression patterns from cross-
sectional imaging data.4 SuStaIn simultaneously clusters in-
dividuals into groups (subtypes) and reconstructs a disease
progression pattern (set of stages) for each group using dis-
ease progression modeling techniques. Each progression
pattern is described using a piecewise linear z score model,
consisting of a series of stages where each stage corresponds
to a biomarker (volume of a brain region) reaching a new z
score. The optimal number of subtypes was determined using
information criteria calculated through cross-validation12 to
balance model complexity with internal model accuracy, as in
reference 4. The subtype progression patterns identified by
SuStaIn were visualized using BrainPainter.13
Assigning Individuals to Subtypes and Stages
Individuals were subtyped by comparing the likelihood they
belonged to each SuStaIn subtype (summing over SuStaIn
stage) with the likelihood they were at SuStaIn stage
0 (i.e., had no imaging abnormalities). We called individuals
with a higher probability of belonging to SuStaIn stage
0 than any of the SuStaIn subtypes “normal-appearing,” and
individuals with a higher probability of belonging to a SuS-
taIn subtype than to SuStaIn stage 0 as “subtypable.” Each
subtypable individual was then assigned to their most
probable subtype. Individuals were staged by computing
their average SuStaIn stage, weighted by the probability they
belonged to each stage of each subtype.
Statistical Analysis
We compared the demographics of participants assigned to
each group (normal-appearing and each of the SuStaIn
subtypes). To compare whether there were any differences
between groups, we performed pairwise comparisons be-
tween groups using t tests for continuous variables and χ2
tests for categorical variables. We tested whether any mu-
tations had a significantly different proportion of individuals
assigned to each subtype by performing a χ2 test comparing
the number of individuals assigned to each subtype for each
mutation vs all the other mutations. We performed 2 sets of
analyses to compare the clinical and neuropsychological test
scores between individuals assigned to each of the SuStaIn
subtypes. In the first set of analyses, we used Mann-Whitney
U tests to perform pairwise comparisons between the subset
of noncarriers who were relatives of individuals with MAPT
mutations (n = 48) and symptomatic MAPT mutation car-
riers assigned to each SuStaIn subtype (n = 25 in total).
In the second set of analyses, we accounted for SuStaIn
stage, age, and sex, by fitting the linear model score ; sub-
type + stage + age + sex for each test, including data from all
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subtypable mutation carriers (n = 34; 9 presymptomatic and
25 symptomatic). We report statistical significance at a level
of p < 0.05, and at the Bonferroni corrected level of p < 0.001
for the clinical scores (43 items), and p < 0.005 for the
neuropsychology scores (11 items) to account for multiple
comparisons.
Data Availability
Data can be obtained according to the GENFI data sharing
agreement, after review by the GENFI data access committee
with final approval granted by the GENFI steering committee.




Table 1 shows the demographics of the participants included
in this study. SuStaIn was applied to 82 MAPT mutation
carriers (25 symptomatic, 57 presymptomatic), consisting
predominantly of individuals with P301L (n = 38), IVS10+16
Figure 1 Subtype Progression Patterns Identified by Subtype and Stage Inference (SuStaIn)
Each progression pattern consists of a set of stages at which regional brain volumes in MAPT mutation carriers (symptomatic and presymptomatic) reach
different z scores relative to noncarriers. (A) Spatial distribution and severity of atrophy at each SuStaIn stage based on the most likely subtype progression
patterns predicted by the SuStaIn algorithm. (B) Uncertainty in the SuStaIn subtype progression patterns for each region, where each region is shaded
according to the probability a particular z score is reached at a particular SuStaIn stage, ranging from0 (white) to 1 (red for a z score of 1,magenta for a z score
of 2, blue for a z score of 3, and black for a z score of 5). Visualizations in subfigure A were generated using BrainPainter.13 Ant = anterior; Cing = cingulate;
DLPFC = dorsolateral prefrontal cortex; FRP = frontal pole; Post = posterior; VMPFC = ventromedial prefrontal cortex.
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(n = 20), and R406W (n = 9) mutations, but there were
also additional rarer mutations, which are not fully dis-
closed to avoid unblinding of the genetic status. The large
majority of symptomatic mutation carriers (23 out of 25)
had a diagnosis of behavioral variant FTD, with 1 in-
dividual having a diagnosis of corticobasal syndrome, and
another having a diagnosis of dementia that was not oth-
erwise specified.
Subtype Progression Patterns
SuStaIn identified 2 groups ofMAPT mutation carriers with
distinct patterns of regional atrophy (Figure 1). The first
group, which we termed the “temporal subtype,” had atro-
phy in the hippocampus, amygdala, medial and lateral tem-
poral cortex, and temporal pole as well as anterior and
posterior insular cortex at early SuStaIn stages. The second
group, which we termed the “frontotemporal subtype,” had
atrophy in the orbitofrontal cortex, ventromedial prefrontal
cortex, lateral temporal lobe, anterior insula cortex, and
anterior cingulate at early SuStaIn stages. Thus, early atro-
phy in the anterior insula and lateral temporal lobe was a
common feature of both subtypes; early atrophy in the
medial temporal lobe, temporal pole, posterior insula, hip-
pocampus, and amygdala was a distinctive feature of the
temporal subtype; and early atrophy in frontal regions and
the anterior cingulate was a distinctive feature of the fron-
totemporal subtype.
Subtype Prevalence
Among the 25 symptomatic mutation carriers, 0 (0%) were
categorized as normal-appearing (i.e., assigned to very early
SuStaIn stages at which there is low confidence in the subtype
assignment), 20 (80%) were assigned to the temporal sub-
type, and 5 (20%) were assigned to the frontotemporal sub-
type. Of the 57 presymptomatic mutation carriers, 48 (84%)
were assigned to the normal-appearing group, 3 (5%) were
assigned to the temporal subtype, and 6 (11%) were assigned
to the frontotemporal subtype. Overall this gave a total of 33
subtypable (i.e., with detectable imaging abnormalities) mu-
tation carriers, with a total of 23 individuals (68%) in the
temporal subtype and 11 individuals (32%) in the fronto-
temporal subtype at baseline.
Subtype Demographics
Table 1 shows the demographics of the normal-appearing
group, temporal subtype, and frontotemporal subtype. There
were significant differences in age at visit, proportion of
symptomatic individuals, and estimated years from onset
(EYO) among the 3 groups, but no differences in the pro-
portion of men and women. The normal-appearing group was
the youngest (mean age 38.3 ± 11.1 years), contained no
symptomatic individuals, and had the longest estimated time
until onset (average EYO of −15.0 ± 11.2 years). The tem-
poral group was the oldest (mean age 59.0 ± 8.9 years), had
the highest (87%) proportion of symptomatic individuals, and











Presymptomatic 48 (100) 9 (26) ≤0.001 3 (13) 6 (55) 0.032
Symptomatic 0 (0) 25 (74) 20 (87) 5 (45)
Age, y
Presymptomatic 38.3 (11.1) 44.6 (8.4) 0.074 42.9 (1.4) 45.4 (10.5) 0.599
Symptomatic NA 59.2 (8.7) NA 61.4 (6.7) 50.4 (11.2) 0.093
Sex, female
Presymptomatic 30 (62.5) 4 (44.4) 0.520 1 (33.3) 3 (50.0) 1.000
Symptomatic NA 9 (36.0) NA 8 (40.0) 1 (20.0) 0.755
EYO, y
Presymptomatic −15.0 (11.2) −4.7 (8.3) 0.006a −3.3 (1.4) −5.4 (10.4) 0.640
Symptomatic NA 5.4 (5.0) NA 6.1 (5.2) 2.8 (2.9) 0.090
SuStaIn stage
Presymptomatic 0.2 (0.5) 14.6 (12.0) 0.007a 16.3 (12.6) 13.8 (12.8) 0.792
Symptomatic NA 24.9 (11.1) NA 25.3 (9.4) 23.4 (17.6) 0.822
Abbreviations: EYO = estimated years from onset; NA = not applicable (due to there being no symptomatic individuals in the normal-appearing category);
SuStaIn = Subtype and Stage Inference.
Values are n (%) or mean (SD). Pairwise comparisons between groups were performed using t tests for continuous variables and χ2 tests for categorical
variables.
a Significant.
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had the least estimated time until onset (average EYO of 4.8 ±
5.8 years, i.e., past onset). The frontotemporal group had a
mean age of 47.7 ± 10.6 years, 45% symptomatic individuals,
and an average EYO of −1.7 ± 8.7 years. SuStaIn stage was
significantly correlated with EYO in the subtypable mutation
carriers (r = 0.54, p ≤ 0.001, n = 34), with a similar correlation
coefficient when analyzing each subtype individually (tem-
poral: r = 0.49, p = 0.017, n = 23; frontotemporal: r = 0.51, p =
0.110, n = 11).
Association Between MAPT Mutation and
Subtype Assignment
We compared the subtype assignments (temporal vs fronto-
temporal) of individuals with different MAPT mutations, ex-
cluding the normal-appearing individuals assigned to very
early SuStaIn stages at which there is low confidence in their
subtype assignment. Table 2 compares the MAPT mutations
of individuals assigned to each subtype. There was a one-to-
one mapping between IVS10+16 and R406W mutations and
assignment to the temporal subtype: 9/9 subtypable
IVS10+16 mutation carriers and 7/7 subtypable R406W
mutation carriers were assigned to the temporal subtype (p =
0.016 for IVS10+16 vs all other mutations and p = 0.040 for
R406W vs all other mutations). There was a strong associa-
tion between P301L mutations and assignment to the fron-
totemporal subtype (p < 0.001 vs all other mutations): 9/10
subtypable P301L mutation carriers were assigned to the
frontotemporal subtype, with 1 subtypable P301L mutation
carrier being assigned to the temporal subtype.
Longitudinal Consistency of Subtypes
Fifty of the 82MAPT mutation carriers had annual follow-up
MRI scans at 1 or more time points, with a total of 92 follow-
up scans available. Subtype assignments were generally stable
at follow-up (Table 3), with subtype assignment remaining
the same at 88 of the 92 follow-up visits. At the other 4 visits, 3
individuals progressed from the normal-appearing group to
the temporal subtype, and 1 individual assigned to the fron-
totemporal subtype reverted to normal-appearing. No indi-
viduals changed from the temporal subtype to the
frontotemporal subtype or vice versa. The individual who
reverted from the frontotemporal subtype to normal-
appearing at follow-up was only weakly assigned to the
frontotemporal subtype at baseline, with a probability of 0.55
for frontotemporal and 0.38 for normal-appearing. Of the 3
individuals who progressed to the temporal subtype, 2 had
IVS10+16 mutations and 1 had a rare mutation (undisclosed
to avoid unblinding of genetic status). All 3 individuals were
presymptomatic at baseline and remained presymptomatic at
all available follow-up visits. Figure 2 shows the SuStaIn stages
of individuals at follow-up compared to baseline. As expected,
most individuals either progressed in stage or remained at the
same stage at follow-up (i.e., are on or above the line y = x).
Conversion From Presymptomatic to
Symptomatic Stage
Two individuals converted from being presymptomatic to
symptomatic within the current observational period of the
study, both of whom were identified by SuStaIn as abnormal
at baseline (i.e., were assigned to a subtype rather than to the
normal-appearing group). Although both individuals had
G272V mutations, 1 was assigned to the temporal subtype
and the other to the frontotemporal subtype. Each individual
had 1 available follow-up visit at which their respective sub-
type assignments remained the same.
Neuropsychological Profile of Subtypes
Table 4 shows the relationship between neuropsychological
test scores and SuStaIn subtype and stage across all sub-
typable carriers (presymptomatic and symptomatic), ac-
counting for age and sex. eTable 2 (doi.org/10.5061/dryad.
rxwdbrv83) reports the mean and median test scores in
Table 2 Number of Carriers With Each Mutation Assigned to Each Subtype
Mutation Subtypable, n
Temporal
subtype, n % Temporal
Frontotemporal
subtype, n % Frontotemporal
p Value vs all other
mutations
L266V 1 0 0 1 100 0.140
G272V 3 2 67 1 33 0.970
P301L 10 1 10 9 90 <0.001a
IVS10+16 9 9 100 0 0 0.016a
Q351R 2 2 100 0 0 0.310
V363I 1 1 100 0 0 0.480
P397S 1 1 100 0 0 0.480
R406W 7 7 100 0 0 0.040a
Total 34 23 68 11 32
Entries are listed in order of their location in the MAPT gene. P301L mutations were significantly enriched for the frontotemporal subtype; IVS10+16 and
R406W were significantly enriched for the temporal subtype.
a Significant.
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symptomatic carriers assigned to each subtype. Performance on
the Digit Span forward and Block Design tasks was worse in the
frontotemporal subtype but unrelated to SuStaIn stage, sug-
gesting that performance on these tests has a stronger decline
with disease progression in the frontotemporal subtype. Per-
formance on the Boston Naming Test and both category and
phonemic fluency tests was related to SuStaIn stage but not
SuStaIn subtype, suggesting that these tests decline with disease
progression in both subtypes. Performance on the TMT A and
B and Digit Symbol tasks was worse in the frontotemporal
subtype and related to SuStaIn stage, suggesting that these
scores decline with disease progression in both subtypes but the
overall scores are worse in the frontotemporal subtype. The
associations between SuStaIn subtype and scores on the Digit
Span forward and Block Design tests and SuStaIn stage and
number of errors on the TMT A and B survived Bonferroni
correction for multiple comparisons. In eTable 2, we further
report group comparisons of test scores in symptomatic mu-
tation carriers between subtypes, without correction for SuS-
taIn stage, age, or sex. Among symptomatic carriers, the Digit
Span forward score remains significantly different between the
temporal and frontotemporal subtype (p = 0.009) without
correcting for confounders.
Clinical Characteristics of Subtypes
Table 5 shows the relationship between neuropsychological
test scores and SuStaIn subtype and stage across all sub-
typable carriers (presymptomatic and symptomatic), ac-
counting for age and sex. eTable 3 (doi.org/10.5061/dryad.
rxwdbrv83) reports the mean and median scores in symp-
tomatic carriers assigned to each subtype. Memory impair-
ment score on the GENFI symptom scales (equivalent to the
memory item on the CDR) and memory and orientation
score on the CBI-R were worse in the temporal subtype
but showed no relationship with SuStaIn stage, suggesting
that memory decline is a feature of the temporal subtype
only. Several clinical symptoms worsened with SuStaIn
stage but were not related to SuStaIn subtype, suggesting
that these are features of both subtypes. These symptoms
were disinhibition, ritualistic or compulsive behavior, de-
lusions, impaired grammar/syntax, dysgraphia, impaired
functional communication, dysphagia on the GENFI
symptom scales, and abnormal behavior and abnormal
beliefs on the CBI-R. However, a large number of tests was
performed, and consequently none survived Bonferroni
correction for multiple comparisons. In eTable 3, we fur-
ther report group comparisons of test scores in symp-
tomatic mutation carriers between subtypes, without
correction for SuStaIn stage, age, or sex. The memory
impairment scores on both the GENFI symptom scales
and the CBI-R remain significantly different (p = 0.003 and
p = 0.007, respectively) between symptomatic carriers
assigned to the temporal and frontotemporal subtype
without correcting for confounders.
Discussion
We identified 2 distinct patterns of regional neuro-
degeneration inMAPTmutation carriers: a temporal subtype
Table 3 Longitudinal Consistency of Subtype Assignments
Classification at previous visit
Classification at follow-up visit
Normal-appearing Temporal Frontotemporal
Normal-appearing 53 (53, 0)a 3 (3, 0)a 0 (0, 0)a
Temporal 0 (0, 0) 28 (7, 21)a 0 (0, 0)
Frontotemporal 1 (1, 0) 0 (0, 0) 7 (4, 3)a
An observation is considered to be longitudinally consistent (a) if individuals remain in the same group or progress from the normal-appearing group to the
temporal or frontotemporal subtype. Table entries indicate the number of visits, with the number of participants who were presymptomatic and symp-
tomatic at the previous visit in parentheses. Overall, 91 of 92 visits were longitudinally consistent.
Figure 2 Stage Progression at Follow-Up Visits
Each point represents an individual’s Subtype and Stage Inference (SuStaIn)
stage at baseline and follow-up, with the color indicating the time between
baseline and follow-up.
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and a frontotemporal subtype. Each pattern was associated
with different MAPT mutations and distinct cognitive and
clinical symptoms. Our results provide new insights into the
progression of tau pathology in MAPT mutations while also
having potential utility for patient stratification.
The temporal and frontotemporal progression patterns
identified by SuStaIn demonstrate that there are both com-
mon and distinct features between the 2 subtypes. Both
subtypes have early volume loss in the anterior insula and
lateral temporal lobe, but in the early stages of the temporal
subtype, this atrophy is more widespread across other tem-
poral lobe regions, including the hippocampus and amygdala,
as well as the posterior insula, while in the early stages of the
frontotemporal subtype there is additional atrophy in frontal
regions. Our findings are broadly in agreement with the pat-
terns identified in the studies by Whitwell et al.7 and Chu
et al.,14 but account for variability in disease stage across in-
dividuals and use a larger sample size. Using SuStaIn, we are
able to automatically group the mutations and reconstruct the
full progression of atrophy including very early stages, which
we can identify in presymptomatic individuals.
A higher proportion of presymptomatic mutation carriers was
assigned to the frontotemporal subtype, and consequently the
frontotemporal group was younger and further from onset
than those assigned to the temporal subtype. This could in-
dicate that the frontotemporal group tended to have less
noticeable symptoms relative to the amount of neuro-
degeneration, either because they have greater cognitive
reserve or because the symptoms are atypical compared to the
expected set of symptoms inMAPT mutations. Alternatively,
a higher proportion of presymptomatic individuals may in-
dicate a longer presymptomatic phase among those assigned
to the frontotemporal group.
SuStaIn identified one-to-one mapping between assignment
to the temporal subtype and IVS10+16 and R406W muta-
tions, demonstrating that these 2mutations have a predictable
atrophy pattern. This is in agreement with previous studies
showing focal atrophy in the temporal lobe (particularly
medially) in IVS10+16 and R406W mutation carriers.7,15
Q351R, V363I, and P397S mutations (found in either exon
13, similarly to R406W, or exon 12) also had a one-to-one
mapping to the temporal subtype, but there were only a few
individuals with these mutations in the study.
SuStaIn identified a strong relationship between P301L mu-
tations and assignment to the frontotemporal subtype, with 9
out of 10 subtypable P301L mutation carriers being assigned
to the frontotemporal subtype. This is in agreement with the
results of Whitwell et al.7 and Chu et al.,14 who also identified
P301L mutation carriers as having a different atrophy pattern
vs those with intronic mutations. Interestingly, individuals
assigned to the frontotemporal subtype all had mutations
occurring earlier in theMAPT gene (L266V and G272V, both
in exon 9, and P301L in exon 10), suggesting a possible re-
lationship between location in the MAPT gene and atrophy
pattern. It was also notable that no mutation had a one-to-
one mapping to the frontotemporal subtype, whereas
Table 4 Comparison of Neuropsychological Test Scores of Individuals Assigned to Each Subtype and Stage Inference
(SuStaIn) Subtype and SuStaIn Stage
SuStaIn subtype SuStaIn stage
Group with worse score Change with SuStaIn staget Value p Value t Value p Value
Digit Span forward −3.56 0.001b −0.26 0.799 Frontotemporal
Digit Span backward −2.04 0.051 0.10 0.918
TMT part A (time) 1.31 0.200 2.13 0.042a Worsens
TMT part A (errors) 1.98 0.058 3.53 0.001b Worsens
TMT part B (time) 2.08 0.047a 1.47 0.153 Frontotemporal
TMT part B (errors) 1.88 0.071 3.39 0.002b Worsens
Digit Symbol −2.32 0.028a −2.61 0.015a Frontotemporal Worsens
Boston Naming Test 0.64 0.529 −2.60 0.015a Worsens
Category fluency −0.27 0.790 −3.75 0.008a Worsens
Phonemic fluency −1.06 0.299 −2.77 0.010a Worsens
Block design −3.52 0.002b −1.65 0.111 Frontotemporal
Abbreviation: TMT = Trail Making Test.
Age and sex were included as additional covariates.
a Statistically significant at p < 0.05, uncorrected for multiple comparisons.
b Statistically significant at p < 0.05, corrected for multiple comparisons.
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Table 5 Comparison of Clinical Scales Scores of Individuals Assigned to Each Subtype and Stage Inference (SuStaIn)
Subtype and SuStaIn Stage
SuStaIn subtype SuStaIn stage
Group with worse score Change with SuStaIn staget Value p Value t Value p Value
Behavioral
Disinhibition −0.76 0.453 2.08 0.047a Worsens
Apathy −0.34 0.739 1.83 0.077
Loss of empathy −0.47 0.642 0.92 0.363
Ritualistic or compulsive behaviour −1.24 0.225 2.16 0.039a Worsens
Hyperorality or appetite change −1.67 0.106 1.29 0.207
Neuropsychiatric
Visual hallucinations 0.59 0.557 −0.88 0.385
Delusions 0.64 0.526 2.65 0.013a Worsens
Depression −0.87 0.393 0.01 0.989
Anxiety −0.12 0.903 1.57 0.127
Language
Impaired articulation −0.84 0.406 −0.40 0.691
Decreased fluency 0.93 0.359 1.50 0.146
Impaired grammar/syntax 0.75 0.461 2.41 0.023a Worsens
Impaired word retrieval 0.31 0.758 1.74 0.092
Impaired speech repetition 0.72 0.480 1.85 0.075
Impaired sentence comprehension 0.15 0.882 1.02 0.317
Impaired single word comprehension −0.90 0.373 1.49 0.146
Dyslexia −0.76 0.453 0.07 0.948
Dysgraphia 0.51 0.611 2.68 0.012a Worsens
Impaired functional communication 0.66 0.512 2.38 0.024a Worsens
Cognitive
Memory impairment −2.70 0.012a 1.07 0.295 Temporal
Visuospatial/perceptual impairment −0.84 0.408 0.47 0.641
Impaired judgment/problem solving −1.13 0.270 1.61 0.119
Impaired attention/concentration −1.26 0.216 1.55 0.133
Motor
Dysarthria −0.69 0.496 −0.37 0.714
Dysphagia 0.51 0.611 2.68 0.012a Worsens
Tremor −0.75 0.457 −0.10 0.921
Slowness −0.98 0.337 0.73 0.473
Weakness −0.05 0.957 0.64 0.530
Gait disorder −1.01 0.322 0.24 0.809
Falls −0.44 0.660 0.15 0.882
Continued
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IVS10+16, Q351R, V363I, P397S, and R406W mutations all
had a one-to-one mapping to the temporal subtype. This
could be suggestive of multiple competing biological pro-
cesses in L266V, G272V, and P301L mutations, producing
either a temporal or a frontotemporal subtype. The pheno-
type produced by these mutations may be modified by ad-
ditional genetic or environmental factors.16 Alternatively,
the lack of a one-to-one mapping could simply be due to
there being fewer samples from this group to train the
SuStaIn algorithm on, making it more difficult to charac-
terize the frontotemporal atrophy pattern.
The SuStaIn algorithm showed strong subtyping and staging
capabilities: the subtype assignments were longitudinally
consistent at 91 of the 92 follow-up visits, with 88 individuals
remaining the same subtype and 3 individuals progressing
from normal-appearing to subtypable. The individual who
reverted from the frontotemporal subtype to normal-appearing
at follow-upwas only weakly assigned (probability of 0.55) to the
frontotemporal subtype at baseline. Moreover, the 2 individuals
who converted from being presymptomatic to symptomatic
during the study were both subtypable (rather than normal-
appearing) at baseline, suggesting that the SuStaIn algorithm
might have utility for predicting symptom onset.
The frontotemporal group had worse performance on the Digit
Span, TMT, Digit Symbol, and Block Design tasks compared to
the temporal group, indicating greater deficits in tests that are
likely to tap into executive function, consistent with the
neuroanatomical findings of greater frontal lobe involvement.
However, the temporal group had greater symptoms of memory
impairment on the GENFI symptom scales and worse memory
scores on the CBI-R. This is consistent with prior reports of
episodic memory impairment in people with MAPT
mutations,17,18 a feature that is generally unusual and atypical in
FTD, but may well be a specific feature of certain MAPT
mutations.
There are a number of limitations to our study and oppor-
tunities for future work. Subtyping was performed by simply
assigning individuals to their most probable SuStaIn subtype
given their imaging data; however, alternative methods for
assigning subtypes using SuStaIn could be explored in the
future, such as only subtyping individuals with a high proba-
bility of matching one of the subtypes. These types of ap-
proaches may be particularly beneficial when using SuStaIn in
new populations with different demographics or unseen MAPT
mutations. The statistical analysis of neuropsychological and
clinical scores modeled SuStaIn subtype and stage simultaneously
in order to pool data across the limited sample size, assuming that
the test scores decline at the same rate within each subtype but
have a different average value. There may be different rates of
decline of test scores with stage within each subtype, which should
be tested in future studieswith larger sample sizes.While our study
gathered the largest sample ofMAPTmutation carriers to date, the
numbers are still small and some mutations were absent from our
study, such as the V337M mutation, and thus the subtypes may
not be generalizable to individuals with these unseen mutations.
Table 5 Comparison of Clinical Scales Scores of Individuals Assigned to Each Subtype and Stage Inference (SuStaIn)
Subtype and SuStaIn Stage (continued)
SuStaIn subtype SuStaIn stage
Group with worse score Change with SuStaIn staget Value p Value t Value p Value
CBI-R
Memory and orientation −2.61 0.015a 0.85 0.401 Temporal
Everyday skills −0.86 0.397 1.42 0.168
Self-care −0.01 0.995 0.68 0.502
Abnormal behaviour −0.78 0.444 2.32 0.028a Worsens
Mood 0.06 0.954 1.88 0.071
Beliefs 0.22 0.826 2.59 0.015a Worsens
Eating habits −1.45 0.160 1.89 0.070
Sleep 0.23 0.824 0.78 0.441
Stereotypic and motor behaviors −1.15 0.260 2.03 0.052
Motivation −1.29 0.209 0.01 0.993
Total CBI-R score −1.44 0.160 1.83 0.078
Abbreviation: CBI-R = Cambridge Behavioural Inventory–Revised.
Age and sex were included as additional covariates.
a Statistically significant at p < 0.05, uncorrected for multiple comparisons.
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Overall, our results provide strong evidence of distinct pat-
terns of atrophy in P301L mutations compared to IVS10+16
and R406W mutations in the largest sample of MAPT mu-
tation carriers collected to date. We demonstrate that these
distinct atrophy patterns produce different clinical pheno-
types, with the temporal subtype being associated with im-
paired episodic memory and the frontotemporal subtype
being associated with more executive dysfunction. The sub-
typing and staging information provided by the SuStaIn al-
gorithm shows potential clinical utility for identifying
individuals at risk of conversion and predicting their mutation,
as well as for patient stratification in forthcoming therapeutic
trials. Our results further demonstrate the power of the
SuStaIn algorithm for identifying novel relationships between
imaging phenotypes, genetics, and clinical presentation.
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